文献速递乳腺癌

CALGB 40601:HER2阳性乳腺癌新辅助双靶向治疗的生存、病理缓解与基因组学

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.
PubMed 文献 · J Clin Oncol · 2020-10-23

中位随访超过7年,THL较TH显著改善无复发生存(RFS)和总生存(OS),TH与TL无差异。264例治疗前样本mRNA测序显示,免疫相关基因表达特征与更高pCR率和更好RFS相关,而HER2富集特征与更高pCR率但更短RFS相关。

要点

  • THL双靶向较TH单靶向显著改善RFS和OS,TH与TL无差异。
  • 8个免疫相关基因表达特征与更高pCR率和更好RFS显著相关。
  • HER2富集特征与更高pCR率但显著更短RFS相关。

核心结论

  • 在CALGB 40601中,双HER2靶向治疗(THL)较单靶向TH显著改善RFS和OS。
  • 整合内在亚型和免疫特征可预测pCR和RFS,包括残余病灶组。

研究设计与样本

  • 主要终点为pCR,次要终点包括RFS、OS和基因表达分析;264例治疗前样本行mRNA测序。

主要发现

  • 688个基因表达特征中,215个与pCR显著相关,45个与RFS相关,仅22个(3.2%)与两者均相关。
  • 8个免疫特征与更高pCR率和更好RFS显著相关;残余病灶中,免疫球蛋白G特征是独立良好预后因素,HER2富集特征与更高pCR率但显著更短RFS相关。

临床怎么用

  • 双HER2靶向联合紫杉醇可作为HER2阳性乳腺癌新辅助治疗的强化选择。
  • 内在亚型和免疫特征有助于预测pCR和RFS,可能指导治疗升阶梯或降阶梯策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: CALGB 40601 assessed whether dual versus single human epidermal growth factor receptor 2 (HER2) -targeting drugs added to neoadjuvant chemotherapy increased pathologic complete response (pCR). Here, we report relapse-free survival (RFS), overall survival (OS), and gene expression signatures that predict pCR and survival. PATIENTS AND METHODS: Three hundred five women with untreated stage II and III HER2-positive breast cancer were randomly assigned to receive weekly paclitaxel combined with trastuzumab plus lapatinib (THL), trastuzumab (TH), or lapatinib (TL). The primary end point was pCR, and secondary end points included RFS, OS, and gene expression analyses. mRNA sequencing was performed on 264 pretreatment samples. RESULTS: One hundred eighteen patients were randomly allocated to THL, 120 to TH, and 67 to TL. At more than 7 years of follow-up, THL had significantly better RFS and OS than did TH (RFS hazard ratio, 0.32; 95% CI, 0.14 to 0.71; P = .005; OS hazard ratio, 0.34; 95% CI, 0.12 to 0.94; P = .037), with no difference between TH and TL. Of 688 previously described gene expression signatures, significant associations were found in 215 with pCR, 45 with RFS, and only 22 with both pCR and RFS (3.2%). Specifically, eight immune signatures were significantly correlated with a higher pCR rate and better RFS. Among patients with residual disease, the immunoglobulin G signature was an independent, good prognostic factor, whereas the HER2-enriched signature, which was associated with a higher pCR rate, showed a significantly shorter RFS. CONCLUSION: In CALGB 40601, dual HER2-targeting resulted in significant RFS and OS benefits. Integration of intrinsic subtype and immune signatures allowed for the prediction of pCR and RFS, both overall and within the residual disease group. These approaches may provide means for rational escalation and de-escalation treatment strategies in HER2-positive breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Fernandez-Martinez A, Krop IE, Hillman DW, et al. Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer. J Clin Oncol. 2020. PMID: 33095682. doi:10.1200/JCO.20.01276

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。